Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
Picking up post #4: that is the part I would want checked first.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
This follows post #9 rather than contradicting it.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
I read post #31 twice before replying, because I had assumed the opposite.
Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.
Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.
Read the full topic (46 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019)…
|
+77 | 84 | 54k | 11mo |
|
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…
|
+28 | 33 | 1.6k | 1mo |
|
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…
|
+20 | 24 | 47k | 4mo |
|
Why plausible mechanism is not evidence of effect — one year on
The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read…
|
+3 | 7 | 3.6k | 13mo |
|
Why plausible mechanism is not evidence of effect
Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is much…
|
+14 | 18 | 57k | 13mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold?
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022)…
|
+19 | 23 | 4.2k | 19mo |
|
A structured critique template this community uses — a second dataset
On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
+47 | 51 | 16k | 15h |
|
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…
|
+6 | 10 | 3.1k | 1d |
|
Delayed gastric emptying and oral medication absorption: which drugs matter
On the subject in the title: Delayed gastric emptying and oral medication absorption: which drugs matter Working notes rather than a conclusion. Reporting something rather than asking about it, in case the…
|
+110 | 116 | 43k | 14mo |
|
CJC-1295 with and without DAC: what the modification does
On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with SURMOUNT-OSA ( N Engl J Med ,…
|
+117 | 123 | 5.6k | 22h |